MXPA04001255A - Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma. - Google Patents

Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.

Info

Publication number
MXPA04001255A
MXPA04001255A MXPA04001255A MXPA04001255A MXPA04001255A MX PA04001255 A MXPA04001255 A MX PA04001255A MX PA04001255 A MXPA04001255 A MX PA04001255A MX PA04001255 A MXPA04001255 A MX PA04001255A MX PA04001255 A MXPA04001255 A MX PA04001255A
Authority
MX
Mexico
Prior art keywords
lasik
trauma
injury
compounds
conditions resulting
Prior art date
Application number
MXPA04001255A
Other languages
English (en)
Inventor
R Hellberg Mark
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA04001255A publication Critical patent/MXPA04001255A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion ofrece metodos para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de LASIK y otras cirugias oculares o trauma.
MXPA04001255A 2001-08-29 2002-07-23 Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma. MXPA04001255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29
PCT/US2002/023871 WO2003020281A1 (en) 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Publications (1)

Publication Number Publication Date
MXPA04001255A true MXPA04001255A (es) 2004-05-27

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001255A MXPA04001255A (es) 2001-08-29 2002-07-23 Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.

Country Status (10)

Country Link
EP (1) EP1420791A4 (es)
JP (1) JP2005502678A (es)
CN (1) CN1549718A (es)
AR (1) AR036194A1 (es)
BR (1) BR0212151A (es)
CA (1) CA2455896A1 (es)
MX (1) MXPA04001255A (es)
PL (1) PL368565A1 (es)
WO (1) WO2003020281A1 (es)
ZA (1) ZA200400837B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370245T3 (es) * 2003-04-18 2011-12-13 Senju Pharmaceutical Co., Ltd. 2-cloro-6,7-dimetoxi-n-[5-(1)h-indazolil]quinazolina-4-amina, dihidrocloruro de n-(1-bencil-4-piperidinil)-1h-indazol-5-amina, ácido 4-[2-(2,3,4,5,6-pentafluorofenil)acriloil]cinámico e hidrocloruro de fasudilo para uso en la recuperación de la percepción corneal.
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
KR20070036031A (ko) * 2004-04-23 2007-04-02 센주 세이야꾸 가부시키가이샤 Ｐａｃａｐ 및 이의 유도체를 함유하는 각막 신경세포 형성촉진제
US7485654B2 (en) 2004-06-03 2009-02-03 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
EP2072047A1 (en) 2005-03-15 2009-06-24 Ono Pharmaceutical CO., LTD. Therapeutic agent for opthalmic disease
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2001085152A2 (en) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil for treating glaucoma

Also Published As

Publication number Publication date
PL368565A1 (en) 2005-04-04
WO2003020281A1 (en) 2003-03-13
CN1549718A (zh) 2004-11-24
CA2455896A1 (en) 2003-03-13
JP2005502678A (ja) 2005-01-27
AR036194A1 (es) 2004-08-18
EP1420791A4 (en) 2004-09-15
ZA200400837B (en) 2005-02-02
EP1420791A1 (en) 2004-05-26
BR0212151A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
TW200733964A (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
DE69521620T2 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE254461T1 (de) Behandlung von augenschmerzen
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
EA200300560A1 (ru) Улучшенный способ лечения
DE602005008935D1 (de) Statine zur behandlung von okularer hypertonie und glaukom
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2003105781A3 (en) OPHTHALMIC COMPOSITIONS FOR TREATING EYE HYPERTENSION
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004091436A3 (en) Methods and compositions for treating ocular disease
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
EP1251862A4 (en) ORTHALMOLOGICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
ATE252387T1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
MXPA04006029A (es) Derivados novedosos de benzofuranimidazolina y benzodifuranimidazolina y su uso para el tratamiento de glaucoma.
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
MXPA04002098A (es) El uso de estrogenos no afeminantes como agentes retinoprotectores para el tratamiento del glaucoma.
DE60012163D1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
WO2002015942A8 (en) Method for the identification of agents that inhibit or promote cataracts and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal